Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HM95573 + cetuximab
- Development stage
- Phase 1
- Lead developer
- Genentech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
HM95573 (belvarafenib) is an investigational, orally available small-molecule inhibitor of RAF serine/threonine protein kinases (including ARAF, BRAF, and CRAF), designed to disrupt the RAF/MEK/ERK signaling pathway that drives tumor proliferation in cancers carrying BRAF, KRAS, or NRAS mutations. Cetuximab is a monoclonal antibody that targets the epidermal growth factor receptor (EGFR), inhibiting EGFR-mediated signaling and thereby impeding cancer cell growth and survival. The combination of HM95573 and cetuximab is being evaluated primarily for solid tumors harboring RAS or RAF pathway mutations, leveraging the dual blockade of RAF and EGFR signaling pathways to overcome resistance mechanisms observed in cancer therapy[1][3][5].
- Other names
- belvarafenib + cetuximab
02
Targets
EGFR (Epidermal growth factor receptor)RAF1 (c-Raf-1 (Y340D/Y341D))
Beyond the preview
Go deeper on HM95573 + cetuximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HM95573 + cetuximab.